IL6 and breast carcinoma: Bachelot et al. studied the clinical meaning of vascular endothelial growth factor (VEGF) and IL-6 expression in hormone-refractory mammary carcinomas and observed that presence of IL-6 in patient’s serum (but not VEGF), was correlated with a shorter survival [25].